Neurolixis CEO to Present at World Orphan Drug Congress USA

DANA POINT, Calif. - April 21, 2015 - PRLog -- Dana Point, CA, April 21, 2015 -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that Dr. Mark A. Varney, PhD., will present at the World Orphan Drug Congress to be held on April 22-24, 2015 in Washington DC. In his capacity as Chief Executive Officer of Neurolixis, Dr. Varney will participate in the ‘Pitch and Partner’ session (April 23, 1:30pm). His presentation is entitled “NLX-101 for the treatment of Rett Syndrome.”

NLX-101 is a clinical candidate being developed by Neurolixis as a treatment for Rett syndrome, a serious orphan disorder that affects about 30 000 girls in Europe and North America. NLX-101 exhibits a remarkably promising profile of therapeutic activity in transgenic mouse models of Rett syndrome, reversing the breathing arrhythmia that is seen in Rett syndrome mice and is a serious symptom of the disorder in human. Investigation of the physiological effects of NLX-101 is being conducted with support from the International Rett Syndrome Foundation and the Rett Syndrome Research Trust.

Neurolixis is actively pursuing opportunities to partner the clinical development of NLX-101 – contact us for further information.

For full details of the World Orphan Drug Congress program see the meeting website (http://www.terrapinn.com/conference/world-orphan-drug-congress-usa).

About NLX-101

NLX-101 acts on the brain’s serotonin system, and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such ‘biased agonism’ in these brain regions is thought to underlie its potent effects in animal models of Rett syndrome (see Levitt ES et al., Journal of Applied Physiology, Oct 10, 2013). NLX-101 is an orally administered agent that has previously been tested in a Phase 1 clinical study in healthy volunteers. Neurolixis plans to investigate its ability to normalize irregular breathing patterns and other functions in patients with Rett syndrome.

About Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder that affects brain development, and primarily affects girls.  Most babies with Rett syndrome to develop normally at first, but symptoms appear between 6 and 18 months of age. Children with Rett syndrome develop a wide range of symptoms that include abnormal and distressing breathing patterns, as well as loss of speech and poor movement coordination. There is no cure for Rett syndrome.  The incidence of Rett is estimated at 1 in 10,000 females; in the European Union approximately 16,000 girls and women affected with a similar number in the United States.

About Neurolixis, Inc.

Neurolixis, located in San Diego, California, is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of psychiatric disorders such as depression and schizophrenia, and neurological disorders such as Parkinson’s disease and Rett syndrome. Additional information regarding Neurolixis is available at http://www.neurolixis.com

Forward Looking Statement

  Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.